Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
atezolizumab + ipatasertib + paclitaxel
- Development stage
- Phase 3
- Lead developer
- Roche
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Atezolizumab + ipatasertib + paclitaxel is a triplet combination therapy being investigated primarily for the treatment of triple-negative breast cancer (TNBC). This combination brings together three distinct mechanisms of action: atezolizumab is a PD-L1 inhibitor (immune checkpoint inhibitor), ipatasertib is an AKT inhibitor, and paclitaxel is a taxane chemotherapy agent that stabilizes microtubules. The triplet has been studied in clinical trials including the phase III IPATunity170 trial for locally advanced or metastatic TNBC. The regimen typically consists of intravenous atezolizumab 840 mg (days 1 and 15), oral ipatasertib 400 mg/day (days 1-21), and intravenous paclitaxel administered in a 28-day cycle.
- Other names
- triplet therapytriplet combination
02
Targets
AKT (RAC-alpha serine/threonine-protein kinase)MicrotubuleCD274 (Programmed cell death protein 1 ligand 1)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on atezolizumab + ipatasertib + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on atezolizumab + ipatasertib + paclitaxel.